/
We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation.
The business is unprofitable at the operating level (-5.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 29.8% YoY with margins expanding 17.8pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$26M
▲ +29.8% YoY
Net Income (TTM)
-$922K
▲ +91.5% YoY
Op. Margin
-6.86%
▲ +17.8pp YoY
ROIC
-8.22%
▲ +17.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$555K
▲ +66.2% YoY
Op. Cash Flow (TTM)
$793K
▲ +56.0% YoY
Net Debt
$888K
Cash & Equiv.
$3M
5Y CAGR: +31.6%
Continue Research